Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference

Key Points

• Anixa runs a four‑person, partnership-driven model to keep a very modest cash burn, with insiders buying shares and licensing deals structured to minimize dilution; management expects the Phase II breast cancer trial to begin within 12–18 months.
• The FSHR-targeted ovarian CAR-T has treated 13 late‑stage patients with reported survival extensions (including one patient >2.5 years), and the next cohorts will test higher dosing plus lymphodepletion to improve engraftment while focusing on overall survival.
• The Phase II breast vaccine will be evaluated neoadjuvantly against standard‑of‑care (typically KEYTRUDA) plus vaccine after Phase I showed no added KEYTRUDA toxicity, with a long‑term plan to move from therapeutic use toward recurrence prevention and eventual prophylactic use.

Anixa Biosciences NASDAQ: ANIX CEO Dr. Amit Kumar outlined the company’s strategy for advancing two clinical-stage oncology programs while maintaining what he described as a “very modest” cash burn during a Water Tower Research conference session moderated by Robert Sassoon, Managing Director of Healthcare, Neurosciences, and Special Situations at Water Tower Research.

Lean operating model and capital discipline

Kumar said Anixa operates with just four employees and relies on a partnership-driven model to execute clinical development. He cited work conducted through collaborations with the Cleveland Clinic and Moffitt Cancer Center, along with the use of consultants and third-party manufacturing organizations for clinical trial materials and fill-and-finish services. He added the company expects to bring on a contract research organization (CRO) to support planning and execution of an upcoming Phase II breast cancer vaccine study.

On governance and commitment, Kumar said several insiders, including himself and board members, have purchased shares on the open market. He also emphasized a longstanding corporate goal of limiting cash burn to reduce dilution, saying Anixa has advanced two clinical trials in breast and ovarian cancer “with very minor burn” and expects that approach to continue.

Ovarian cancer CAR-T: early survival observations and next cohort changes

Discussing Anixa’s follicle-stimulating hormone receptor (FSHR)-targeted CAR-T program for late-stage, recurrent ovarian cancer, Kumar highlighted the challenges of CAR-T in solid tumors, noting that no CAR-T therapy has been approved for any solid tumor indication. He said most solid tumor CAR-T trials have “failed, or have been halted, or are not producing good data,” but added that a small number are beginning to show efficacy, including Anixa’s program.

Kumar said Anixa has treated 13 patients to date and believes its results compare favorably with other solid tumor CAR-T efforts, while cautioning that it has not yet achieved a cure in the treated population. He described the patient group as “terminally ill,” stating that when patients enter the trial their median life expectancy is about 12 weeks. He said Anixa has extended survival for many patients, including one case to “over two and a half years.”

He attributed aspects of the approach to learnings from prior failures in solid tumor CAR-T and pointed to two design elements: a target he described as unique to ovarian cancer (FSHR) and local delivery into the peritoneum. In monitoring activity, Kumar said Anixa reviews biomarkers, laboratory tests, and CT scans, but reiterated that overall survival is the primary endpoint the company is focused on. He also described evidence of tumor infiltration visible on imaging, including what he called “pseudoprogression,” where tumors initially appear enlarged due to T-cell infiltration rather than growth.

Looking ahead, Kumar said the next cohort will involve both higher dosing and the introduction of lymphodepletion, a preparative chemotherapy process commonly used in approved hematologic CAR-T therapies. He acknowledged lymphodepletion introduces risks such as temporary infection susceptibility, but said it may enable engineered T-cells to engraft and proliferate more effectively by reducing competition from existing immune cells.

Breast cancer vaccine: neoadjuvant strategy with KEYTRUDA control arm

Kumar said the company’s breast cancer vaccine program is designed to serve both therapeutic and preventative roles over time. For the upcoming Phase II study, he explained Anixa plans to evaluate the vaccine in the neoadjuvant setting, comparing standard-of-care therapy (which he said is typically KEYTRUDA) to standard of care plus the vaccine.

He said the rationale is practical and biological: patients typically receive therapy before surgery to reduce tumor burden, and KEYTRUDA, as a checkpoint inhibitor, helps maintain T-cell activity. Because Anixa’s vaccine is intended to induce antigen-specific, cancer-fighting T-cells, Kumar said the company believes the combination could be synergistic.

Kumar also discussed safety observations from Phase I, where one cohort received KEYTRUDA plus vaccine. He said the purpose was to evaluate whether the combination created intolerable side effects, noting that KEYTRUDA can have difficult side effects and that combinations can worsen tolerability. He reported that Anixa’s vaccine did not increase KEYTRUDA’s side effect profile in that cohort.

On longer-term positioning, Kumar said Anixa expects a “stepwise process” for the vaccine’s target product profile:

• Initial focus: therapeutic use in newly diagnosed patients or those with residual disease
• Next: prevention of recurrence in higher-risk patients
• Long-term goal: a prophylactic vaccine for women who have never had breast cancer

He added that while the neoadjuvant combination approach is viewed as the first target, prophylactic use would likely require the vaccine to be used as a solo agent, because administering KEYTRUDA to healthy individuals would not be acceptable. Kumar said Phase I safety as a monotherapy was “rock-solid safe,” with injection-site irritation as the only notable side effect described.

Positioning versus personalized mRNA approaches

Asked about competition from personalized mRNA cancer vaccines, Kumar said the only approved mRNA vaccines to date are for COVID-19, not cancer. He said the personalized mRNA approach can be complex, involving tumor sampling, sequencing, identification of immunogenic sequences (including with AI), and manufacturing a custom vaccine per patient. Kumar argued that process is burdensome—particularly for prophylaxis—and said the costs can reach “hundreds of thousands of dollars” and take substantial time.

By contrast, Kumar described Anixa’s product as an off-the-shelf peptide vaccine “in a small bottle” that can be stored and administered as patients present for treatment.

Partnership strategy, licensing economics, and upcoming catalysts

Kumar emphasized that conducting trials at major U.S. centers supports credibility, contrasting Anixa’s approach with companies that run studies in lower-cost settings abroad. He said Anixa intends to pursue partnerships with pharmaceutical companies for commercialization rather than building manufacturing and sales infrastructure internally.

On intellectual property and licensing economics, Kumar said the company’s products are licensed from the academic institutions where they were developed—Cleveland Clinic for one program and The Wistar Institute for the CAR-T program—with “very modest milestone payments” and “very modest royalties.” He said the deals were structured to keep most capital directed toward R&D.

As near-term milestones, Kumar said Anixa expects additional CAR-T patient updates as it treats nine more patients in upcoming cohorts, and he pointed to the potential impact of higher dosing and lymphodepletion. For the breast cancer program, he said the company anticipates beginning the Phase II trial within the next 12 to 18 months and expects initial data during that period, adding that Phase II efficacy can be a key valuation inflection point for development-stage companies.

In closing remarks, Kumar said he believes investors underappreciate Anixa largely due to limited awareness, noting the company’s history as an electronics business before he repositioned it as a biotech after becoming CEO in 2017. He also said Anixa has avoided common financing “overhang” such as warrants and preferred stock, citing a major financing completed in 2021 and what he described as support from non-dilutive capital.

About Anixa Biosciences NASDAQ: ANIX

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.